AIM ImmunoTech Announces Update on Ampligen Long Covid Development Program

Today, AIM ImmunoTech, an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, provided an update…

The post AIM ImmunoTech Announces Update on Ampligen Long Covid Development Program appeared first on Solve ME/CFS Initiative.

Read More